Werewolf Swings to Q2 Profit on Jazz Asset Sale; Cash Runway Extended to Q2 2027
HOWL sits 81% above its 52-week low of $0.27.
Summary
Werewolf Therapeutics posted a $3.7M Q2 profit thanks to a $21M asset sale to Jazz, repaid all debt, and extended its cash runway to Q2 2027. The company continues to explore strategic alternatives with Piper Sandler.
Key Events · Earnings and Guidance · HOWL
-
Q2 Net Profit of $3.7M
Net income reached $3.7 million for Q2 2026, a sharp reversal from the $18.0 million net loss in Q2 2025, driven by $21.0 million in collaboration revenue from the Jazz asset sale.
-
Cash Runway Extended to Q2 2027
Cash and cash equivalents stood at $22.0 million as of June 30, 2026, down from $46.5 million at March 31, 2026. The company expects this to fund operations into the second quarter of 2027.
-
Debt Fully Repaid
Proceeds from the Jazz transaction were used to repay all amounts owed under the loan and security agreement with K2 HealthVentures, eliminating $28.2 million in notes payable.
-
Strategic Alternatives Process Ongoing
Werewolf continues to explore strategic alternatives with Piper Sandler as exclusive financial advisor, with updates expected in the second half of 2026.
Analysis · HOWL · Life Sciences
A surprise Q2 net profit of $3.7 million landed at Werewolf Therapeutics, fueled entirely by a $21 million payment from the sale of its JZP898 program to Jazz Pharmaceuticals. While the one-time gain masks an underlying operating loss, it delivered a critical lifeline: the company repaid all debt and extended its cash runway into the second quarter of 2027—a vital reprieve for a biotech that had been under a going-concern warning and was actively exploring strategic alternatives. R&D spending was slashed by more than half, reflecting the earlier 64% workforce reduction, while G&A nearly doubled, likely due to advisory fees for the strategic review. With only $22 million in cash and a market cap near $24 million, the company remains in a precarious position, but the extended runway buys time to advance clinical programs and potentially strike a partnership or sale.
How filings like this one have moved
In the 30 days to Sep 17, 2026, 29.7% of the 1739 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $0.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $24.3M. The 52-week trading range was $0.27 to $2.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.